NCT06453642 - Evaluation of a Simple-Prep Controlled Embolic | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

September 30, 2026

Conditions

EmbolizationVascular TumorRenal AngiomyolipomaRenal Cell CarcinomaBone TumorPortal Vein Embolization

Interventions

DEVICE

GPX® Embolic Device

Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches

Trial Locations (19)

4710

RECRUITING

Christchurch Hospital, Christchurch

10029

RECRUITING

Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

12208

RECRUITING

Albany Medical Center, Albany

22908

RECRUITING

University of Virginia Health System, Charlottesville

27514

RECRUITING

University of North Carolina, Chapel Hill

28203

RECRUITING

Atrium Health Carolinas Medical Center, Charlotte

46202

RECRUITING

Indiana University Hospital, Indianapolis

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

55455

RECRUITING

University of Minnesota, Minneapolis

63110

RECRUITING

Washington University - Barnes Jewish Hospital, St Louis

75390

RECRUITING

University of Texas Southwestern, Dallas

77030

RECRUITING

MD Anderson Cancer Center - Interventional Radiology, Houston

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

92037

RECRUITING

University of California San Diego Altman Clinical and Translation Research Institute, La Jolla

M5B 1W8

RECRUITING

St. Michael's Hospital, Toronto

M5G 1Z5

RECRUITING

Toronto General Hosptial, Toronto

M5G 2C4

RECRUITING

Mount Sinai Hospital Toronto, Toronto

Unknown

RECRUITING

Auckland City Hospital, Auckland